Unilever Dry Shampoo Products Recalled for Benzene Risk
Yale dermatologist Christopher Bunick, MD, PhD, discusses the recurring issue with increased levels of the carcinogen found in self-care and cosmetic products.
The Future of Tailored Alopecia Treatment
In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.
Bimekizumab Provides Sustained Psoriasis Benefit, Tolerability Over 3 Years
New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.
Baricitinib Has Reinvigorated Patients with Alopecia Areata
Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.
Apremilast May Significantly, Safely Benefit Severe Pediatric Psoriasis
New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.
Guselkumab Safety Similar to Placebo for Psoriasis Patients Over 5 Years
Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.
What Does It Take to Initiate JAK Inhibitors for Psoriasis?
Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.
The Implications of Deucravacitinib's Approval for Psoriasis
A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.
Risankizumab Consistently Clears Psoriasis Skin Over 5 Years
Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.
The Emerging Oral & Topical Agents for Psoriasis
Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.
